The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How Tuberculosis Has Shaped Medicine and Society

How Tuberculosis Has Shaped Medicine and Society

May 17, 2017 • By Simon M. Helfgott, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
A 3D illustration of the bacterium, Mycobacterium tuberculosis.

A 3D illustration of the bacterium, Mycobacterium tuberculosis.
Kateryna Kon/shutterstock.com

Pathologists are legendary for blending their work product with the culinary arts. Through the years, their use of delectable foods as descriptors has created a clever way to indelibly link in the minds of clinicians the histopathologic observations of disease with an assortment of these tasty foods: There is the depiction of an apple green birefringence when gazing at amyloid seeped tissue under the microscope, and at autopsy, the nutmeg appearance of an engorged liver suggests longstanding vascular congestion of that organ. When the splenic arteries resemble a thick onion skin, think of lupus or the mysterious Castleman’s disease as its underlying cause. Pathologists are enamored with berries, cherries, jellies, apple cores, spices, chocolates and eggshells; the list is endless.1

You Might Also Like
  • How Wars Have Shaped Rheumatology
  • Precision Medicine Latest Initiative in War on Autoimmunity, Rheumatic Illnesses
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
Explore This Issue
May 2017
Also By This Author
  • Pain is a Tricky Thing to Treat, or Even Evaluate

In this pantheon of pathology foodstuffs resides the noun caseation, a variation of the Latin word, caseus, or cheese. Clinicians’ ears perk up when hearing the term, caseating granuloma, a description that immediately conjures up a dreaded diagnosis, tuberculosis (TB). Caseation necrosis, that cheesy ooze of necrotic cellular debris, is an impressive reminder of the virulence of Mycobacterium tuberculosis (MTB). The human body becomes so overwhelmed, so consumed by this deadly infection, that the term consumption was used to describe it before the eminent microbiologist Robert Koch first identified the infectious origin of TB in 1882.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

TB has tormented humanity through the millennia, sometimes destroying its victims through its sheer microbiological force and other times, battling the host to a draw, and then waiting patiently for when its adversary, the immune system, becomes weakened through the use of immune suppressive drugs or by some other serious illness. Unlike other vicious microbial tormentors—such as the spirochete of syphilis or MTB’s mycobacterial cousin, causing leprosy—that have a predilection for selected tissues, MTB is the least bit fussy. Of course, it prefers to occupy the vast open airspace of the lungs, where it can thrive and multiply as it prepares to be coughed up or spat out, ready to torment a new victim. But MTB is accommodating and can readily occupy and liquefy virtually any other organ space. Say cheese.

Rheumatology & TB

Rheumatologists have had a tangled relationship with TB. Although not considered one of our primary diseases, our continued use of immunosuppressive therapies, especially biological drugs, heightens the risk of our patients contracting the disease. We always include TB in our differential diagnosis of the febrile patient. In the latter half of the 19th century, when TB was responsible for nearly one-quarter of all deaths in Massachusetts and New York, it was often implicated as the cause for just about every chronic illness.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Opinion, Rheuminations Tagged With: Caseation necrosis, History, Immunology, rheumatologist, rheumatology, Treatment, TuberculosisIssue: May 2017

You Might Also Like:
  • How Wars Have Shaped Rheumatology
  • Precision Medicine Latest Initiative in War on Autoimmunity, Rheumatic Illnesses
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • Reinitiating TNF Blockers after Tuberculosis Treatment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)